Testing an immune cell vaccine to prevent ovarian cancer recurrence

Plain-English translation of NCT06639074 on ClinicalTrials.gov ↗ · Source last updated October 2025 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This study is testing a new treatment called folate receptor alpha dendritic cell vaccine (FRαDCs) for people with advanced ovarian, fallopian tube, or primary peritoneal cancer who have completed chemotherapy. The vaccine is designed to train your immune system to recognize and fight cancer cells that express a specific protein. Half of participants will receive the actual vaccine while the other half will receive a placebo (a dummy injection with no active medicine) to see if the treatment works better than placebo.

Advanced ovarian cancer often comes back even after surgery and chemotherapy. This trial is exploring whether training the immune system to target cancer cells might help prevent recurrence and improve survival for patients with these difficult-to-treat cancers.

Do you qualify?

You likely qualify if…

you are 18 years or older
you have been diagnosed with stage III or IV ovarian, fallopian tube, or primary peritoneal cancer and had surgery and one course of platinum-based chemotherapy
you completed chemotherapy at least 4 to 12 weeks before enrolling
you do not have mutations in the BRCA1 or BRCA2 genes
you have adequate blood counts and organ function based on recent lab tests
your doctor expects you to live at least 6 more months

You likely don't qualify if…

you have pathogenic mutations in BRCA1 or BRCA2 genes
you have received treatment for cancer that has already come back or recurred
your blood counts are too low or your organ function is too poor
you are unable or unwilling to return to the study site for regular follow-up visits
you cannot or will not consent to blood draws, biopsies, or imaging scans

What participation looks like

You will have a procedure called leukapheresis to collect immune cells from your blood, which will be used to create your personalized vaccine or placebo. Then you'll receive injections under the skin every 3 weeks for the first 5 cycles, followed by injections every 13 weeks for up to 12 cycles total. Throughout the study, you'll have blood draws, CT or MRI scans, and optional biopsies to monitor your progress and how your immune system responds to the treatment.

AI-generated summary from trial data · Jun 6, 2026 · Not medical advice

Testing an immune cell vaccine to prevent ovarian cancer recurrence

What is this trial?

Do you qualify?

What participation looks like

Trial locations(3 sites)